<div id="readability-page-1"><p>Cim LLC acquired a new stake in  Exelixis, Inc. (NASDAQ:EXEL - Free Report) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 35,092 shares of the biotechnology company's stock, valued at approximately $1,547,000.</p><ul><li>3 Stocks to Buy for a Soft Landing, If There Is One</li></ul><p>A number of other institutional investors have also made changes to their positions in the business. Fuller &amp; Thaler Asset Management Inc. lifted its holdings in  Exelixis by 2.2% during the 1st quarter. Fuller &amp; Thaler Asset Management Inc. now owns 7,795,074 shares of the biotechnology company's stock valued at $287,794,000 after purchasing an additional 164,134 shares during the last quarter.  AQR Capital Management LLC raised its position in shares of  Exelixis by 10.3% in the second quarter. AQR Capital Management LLC now owns 7,606,079 shares of the biotechnology company's stock valued at $335,238,000 after purchasing an additional 712,190 shares during the period.  Geode Capital Management LLC lifted its stake in shares of  Exelixis by 0.4% during the 2nd quarter. Geode Capital Management LLC now owns 7,445,469 shares of the biotechnology company's stock worth $328,196,000 after buying an additional 28,289 shares during the last quarter.  Arrowstreet Capital Limited Partnership boosted its holdings in shares of  Exelixis by 42.9% during the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 5,262,643 shares of the biotechnology company's stock worth $231,951,000 after buying an additional 1,580,567 shares during the period.  Finally, Qube Research &amp; Technologies Ltd boosted its holdings in shares of  Exelixis by 120.5% during the 2nd quarter. Qube Research &amp; Technologies Ltd now owns 3,047,222 shares of the biotechnology company's stock worth $134,306,000 after buying an additional 1,665,110 shares during the period. 85.27% of the stock is owned by institutional investors and hedge funds. </p><h2>Exelixis Stock Performance</h2><p>NASDAQ:EXEL opened at $40.88 on Friday. The company has a market cap of $10.96 billion, a price-to-earnings ratio of 17.25, a PEG ratio of 0.74 and a beta of 0.40. Exelixis, Inc. has a fifty-two week low of $31.90 and a fifty-two week high of $49.62. The stock has a fifty day moving average price of $40.77 and a 200-day moving average price of $40.81. </p><ul><li>3 Strong Biotech Performers To Watch As Sector Nears Breakout</li></ul><p>Exelixis (NASDAQ:EXEL - Get Free Report) last issued its quarterly earnings results on Tuesday, November 4th. The biotechnology company reported $0.78 EPS for the quarter, topping analysts' consensus estimates of $0.68 by $0.10. Exelixis had a return on equity of 31.06% and a net margin of 29.63%.The company had revenue of $597.76 million for the quarter, compared to analysts' expectations of $590.04 million. During the same quarter last year, the business earned $0.47 earnings per share. Exelixis's revenue was up 10.8% on a year-over-year basis.  Research analysts predict that  Exelixis, Inc. will post 2.04 EPS for the current fiscal year. </p><h2>Insider Activity</h2><p>In other Exelixis news, Director Mary C. Beckerle sold 24,622 shares of the company's stock in a transaction on Tuesday, November 11th. The stock was sold at an average price of $41.93, for a total transaction of $1,032,400.46. Following the completion of the sale, the director directly owned 21,380 shares in the company, valued at $896,463.40. This represents a 53.52% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities &amp; Exchange Commission, which is available at the SEC website. Also, EVP Patrick J. Haley sold 34,187 shares of the firm's stock in a transaction on Thursday, November 20th. The shares were sold at an average price of $41.88, for a total value of $1,431,751.56. The SEC filing for this sale provides additional information. Insiders have sold a total of 245,235 shares of company stock valued at $10,490,600 over the last quarter. 2.82% of the stock is owned by corporate insiders. </p><h2>Analysts Set New Price Targets</h2><ul><li>7 Best Cancer Stocks to Invest in Now</li></ul><p>Several research analysts have weighed in on the stock. Wall Street Zen raised shares of Exelixis from a &#34;buy&#34; rating to a &#34;strong-buy&#34; rating in a report on Sunday. Weiss Ratings  reiterated a &#34;buy (b)&#34; rating on shares of Exelixis in a research note on Wednesday, October 8th. Leerink Partnrs upgraded Exelixis from a &#34;hold&#34; rating to a &#34;strong-buy&#34; rating in a research note on Tuesday, October 21st. UBS Group increased their price objective on Exelixis from $35.00 to $40.00 and gave the stock a &#34;neutral&#34; rating in a research report on Thursday, November 6th. Finally, Zacks Research cut shares of Exelixis from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a research report on Tuesday, August 26th. One analyst  has rated the stock with a Strong Buy rating, fifteen have assigned  a Buy rating and twelve have assigned  a Hold rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $45.45.</p><p><b>Read Our Latest Stock Report on EXEL</b></p><h2>Exelixis Profile</h2> (Free Report)<p>Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.</p><h2>Featured Stories</h2><ul><li>Five stocks we like better than Exelixis</li><li>What is a support level?</li><li>Disney's $1 Billion Deal Brings Its Magic to OpenAI</li><li>Differences Between Momentum Investing and Long Term Investing </li><li>Why Amazon Could Be a $300 Stock Within Weeks</li><li>How to Know if a Stock Pays Dividends and When They Are Paid Out</li><li>Adobe Gets Post-Earnings Lift: Long-Term Outlook Favors Upside</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RVhFTA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RVhFTA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Exelixis Right Now?</h2><p>Before you consider Exelixis, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Exelixis wasn't on the list.</p><p>While Exelixis currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

EXEL

<p>Cim LLC acquired 35,092 shares of Exelixis, Inc. (NASDAQ:EXEL) in Q2, valued at $1,547,000. Other institutional investors also increased their positions in Exelixis. The stock opened at $40.88 on Friday with a market cap of $10.96 billion. Exelixis reported strong Q3 earnings, with $0.78 EPS and $597.76 million in revenue. Insiders sold 245,235 shares last quarter. Analysts have given positive ratings and new price targets for the stock.</p>

Cim LLC Acquires Shares of 35,092 Exelixis, Inc. $EXEL